Publications

  • San Miguel J, Weisel K, Moreau P, Lacy M, Song K, Delforge M, Karlin L, Goldschmidt H, Banos A, Oriol A, Alegre A, Chen C, Cavo M, Garderet L, Ivanova V, Martinez-Lopez J, Belch A, Palumbo A, Schey S, Sonneveld P, Yu X, Sternas L, Jacques C, Zaki M, Dimopoulos M.( 2013) Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial. Lancet Oncol. 2013 Oct;14(11):1055-66.
    ABSTRACT CORTESÍA DE PUBMED

  • Mateos, M. V., Hernández, M. T., Giraldo, P., de la Rubia, J., de Arriba, F., Corral, L. L., ... & San Miguel, J. F. (2013). Lenalidomide plus dexamethasone for high-risk smoldering multiple myeloma. New England Journal of Medicine, 369(5), 438-447.
    ABSTRACT CORTESÍA DE PUBMED

  • Paiva B, Martinez-Lopez J, Vidriales MB, Mateos MV, Montalban MA, Fernandez-Redondo E, Alonso L, Oriol A, Teruel AI, de Paz R, Laraña JG, Bengoechea E, Martin A, Mediavilla JD, Palomera L, de Arriba F, Bladé J, Orfao A, Lahuerta JJ, San Miguel JF. (2011) Comparison of immunofixation, serum free light chain, and immunophenotyping for response evaluation and prognostication in multiple myeloma. J Clin Oncol. 2011 Apr 20;29(12):1627-33.
    ABSTRACT CORTESÍA DE PUBMED

  • Juan José Lahuerta, María Victoria Mateos, Joaquín Martínez-López, Laura Rosiñol, Anna Sureda, Javier de la Rubia, José García-Laraña, Rafael Martínez-Martínez, Miguel T. Hernández-García, Dolores Carrera, Joan Besalduch, Felipe de Arriba, José María Ribera, Lourdes Escoda, Belén Hernández-Ruiz, Javier García-Frade, Concepción Rivas-González, Adrian Alegre, Joan Bladé, and Jesús F. San Miguel. Influence of Pre- and Post-Transplantation Responses on Outcome of Patients With Multiple Myeloma: Sequential Improvement of Response and Achievement of Complete Response Are Associated With Longer Survival.
    ABSTRACT CORTESÍA DE PUBMED

  • Puente XS, Pinyol M, Quesada V, Conde L, Ordóñez GR, Villamor N, Escaramis G, Jares P, Beà S, González-Díaz M, Bassaganyas L, Baumann T, Juan M,López-Guerra M, Colomer D, Tubío JM, López C, Navarro A, Tornador C, Aymerich M, Rozman M, Hernández JM, Puente DA, Freije JM, Velasco G, Gutiérrez-Fernández A, Costa D, Carrió A, Guijarro S, Enjuanes A, Hernández L, Yagüe J, Nicolás P, Romeo-Casabona CM, Himmelbauer H, Castillo E, Dohm JC, de Sanjosé S, Piris MA, de Alava E, San Miguel J, Royo R, Gelpí JL, Torrents D, Orozco M, Pisano DG, Valencia A, Guigó R, Bayés M, Heath S, Gut M, Klatt P,Marshall J, Raine K, Stebbings LA, Futreal PA, Stratton MR, Campbell PJ, Gut I, López-Guillermo A, Estivill X, Montserrat E, López-Otín C, Campo E. Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia.
    ABSTRACT CORTESÍA DE PUBMED 

  • Jesús F. San Miguel, Rudolf Schlag, Nuriet K. Khuageva, Meletios A. Dimopoulos, Ofer Shpilberg, Martin Kropff, Ivan Spicka, Maria T. Petrucci, Antonio Palumbo, Olga S. Samoilova, Anna Dmoszynska, Kudrat M. Abdulkadyrov, Rik Schots, Bin Jiang, Maria-Victoria Mateos, Kenneth C. Anderson, Dixie L. Esseltine, Kevin Liu, Andrew Cakana, Helgi van de Velde, and Paul G. Richardson. Bortezomib plus Melphalan and Prednisone for Initial Treatment of Multiple Myeloma. N Engl J Med 2008;359:906-17
    ABSTRACT CORTESÍA DE PUBMED



"One of our areas of research focuses on identifying resistance biomarkers and potential therapeutic targets for multiple myeloma" , Dr. Jesús San Miguel, Principal Investigatorl

Contact

Contact:
Marisol Ripa
Avda. Pío XII, 53
31008 Pamplona
Spain

(+34) 948 194 700 Ext. 1010
msripa@unav.es